ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
19 announcements with these filters
Indegene Limited hosted its Indegene Digital Summit 2026, focusing on operationalizing AI within life sciences. The event also featured the presentation of the VITAL Awards 2026.
Indegene Limited completed the internal merger of its two indirect wholly owned subsidiaries in Germany. This reorganization does not impact Indegene's financial position or operations.
Indegene Limited received preliminary court approval for a class action settlement related to the U.S. Telephone Consumer Protection Act. Final hearing is scheduled for January 2027.
The U.S. Court preliminarily approved the class action settlement for Indegene's subsidiary. The maximum settlement fund is approximately ₹44.84 Crore.
Indegene Limited's subsidiary, Indegene Inc., finalized a class-action settlement framework regarding U.S. fax communication violations. The maximum potential settlement fund is USD 4.72 million (₹44.84 Crore).
Indegene Limited's subsidiary finalized a USD 4.72 million class-action settlement agreement regarding U.S. TCPA violations. The settlement, involving approximately 18,851 unique fax numbers, remains subject to court approval.
Indegene Limited shareholders approved the appointment of Ms. Jill Mary De Simone as an Independent Director for a three-year term starting January 22, 2026.
Indegene Ltd held its 28th Annual General Meeting on August 13, 2026. The meeting transacted business including dividend declaration and appointment of directors.
BPC Genesis Fund I SPV Limited, a non-promoter entity, sold its entire 5.757% stake in Indegene Limited. The open market transaction involved 13,862,223 equity shares.
Indegene delivered its strongest Q1 growth in four years, yet remains burdened by elevated costs from strategic investments and workforce transformation.
Indegene Limited allotted 12,451 equity shares under its ESOP scheme. This allotment marginally increases the company's paid-up share capital.
Indegene reported Q1'FY27 revenue of ₹10,631M (+39.7% YoY) with an EBITDA margin of 16.9%. The strategy focuses on scaling GenAI-powered solutions and deepening engagement with large pharma.
Indegene reported strong Q1 FY27 results with revenue of ₹1,063.1 Crore, up 39.7% YoY. EBITDA rose to ₹179.5 Crore with a 16.9% margin.
Indegene Limited filed its Monitoring Agency Report for the quarter ended June 30, 2026, regarding the utilization of its IPO proceeds.
Indegene Ltd reported revenue from operations of ₹1,063 Cr (+39.7% YoY) and net profit of ₹116.2 Cr (-0.2% YoY) for Q1 FY27.
Indegene Limited scheduled its 28th AGM for August 13, 2026. Key agenda items include declaring a Rs 2.25 per share dividend and director appointments.
Indegene Limited submitted its Business Responsibility and Sustainability Report for FY 2025-26. The report details the company's ESG performance and adherence to NGRBC principles.
Indegene Limited fixed July 31, 2026, as the record date for its ₹2.25 per share final dividend. The 28th AGM is scheduled for August 13, 2026.
Indegene Ltd announces a board meeting on 30 July 2026 to approve unaudited Q2 results and ESOP/RSU allotments. Trading window will resume after results release.